Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report - Wikidata - awgldk - TriplyDB

Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report

Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report

http://www.wikidata.org/entity/Q37065608

about

Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View Long-term Outcomes of Childhood Onset Nephrotic Syndrome FSGS: Diagnosis and Diagnostic Work-Up Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates Update on the treatment of focal segmental glomerulosclerosis in renal transplantation A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues suPAR and Team Nephrology Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease Activation of the IL-2 Receptor in Podocytes: A Potential Mechanism for Podocyte Injury in Idiopathic Nephrotic Syndrome?Immunopathogenesis of idiopathic nephrotic syndrome with relapse.Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist.Renal biopsy: use of biomarkers as a tool for the diagnosis of focal segmental glomerulosclerosis.Permeability factors in focal and segmental glomerulosclerosis.Causes and pathogenesis of focal segmental glomerulosclerosis.Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications.The glomerular permeability factors in idiopathic nephrotic syndrome.Focal segmental glomerular sclerosis: do not overlook the role of immune response.Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology.Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.The hype cycle for soluble urokinase receptor in FSGS: passing the trough of disillusionment?Is there clinical value in measuring suPAR levels in FSGS?A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring.Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.

P2860

Q26738374-D3A0D64A-5426-49E7-98D3-5B18B6429FC3 Q26744025-B212712B-BD5F-44A1-8637-2303F912CA13 Q26744558-6423C41E-547E-4E10-9B96-4A9BA5B0E55B Q26747221-CF9A0D61-0677-4864-90CF-2B1BADAEF5D6 Q26751470-4F629D73-BDF4-414F-A0F9-926BD72C069C Q26776389-AFD80BE9-DC0D-4DBE-9834-65F75F4DC5EE Q33634270-6ACF6843-5D72-42BB-8024-B98DE85825E9 Q33783271-4A3273F3-15A2-4F60-AF0A-C9C96D41EC3B Q33974535-03504AE8-615F-4C36-B08F-EC7A0D619D6F Q34455143-6B6CE5FA-F3BF-41DB-A6CD-9FAC94AB4F6E Q35132279-AB24721D-0A57-4500-A0F2-32CB87231435 Q36070424-7AA7E85C-FDD1-473D-B3EA-CB9205CA5E4C Q37742644-7033E86F-6332-48AA-99F3-E6ED77EE5187 Q38192853-608C05AF-7B0F-4429-B9DC-263AB8D5BA50 Q38203501-E3109B49-D5F0-4A25-9F37-896C728B9DDD Q38244353-0FDFA22C-19C8-454F-8892-02CED57F298B Q38275115-49515ABE-CEDB-48C5-90FA-D2952A80620D Q38371343-95CD1436-ABE4-49B1-9CAF-437FCA2D3686 Q38449629-57D2EC46-DE5D-4F12-8B2C-88E849AFB02F Q38742004-8778CADF-9A81-4A0E-BE84-B10F529A030A Q38991259-06F250F1-50CF-4F59-A127-F85A05FFAA55 Q40528582-650F032A-76FE-47B7-B036-074C94A5540F Q42696925-53C62CCB-F996-4495-A2B0-6625C587B920 Q43063370-11D452D2-BBD1-4909-9ABE-2038431CD6C7 Q43195589-2A4C0A5D-0C1B-492C-99A5-91621D9D2448 Q52874540-A07DC987-ECA1-4CD6-8C56-B1B866BFE3EC Q53663523-D70F2DEC-B6A5-4FD6-B04A-8978450F7064

P2860

Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report

http://www.wikidata.org/entity/Q37065608

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 April 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Serum soluble urokinase-type p ...... ildren: a single-center report

@en

Serum soluble urokinase-type p ...... ldren: a single-center report.

@nl

type

label

Serum soluble urokinase-type p ...... ildren: a single-center report

@en

Serum soluble urokinase-type p ...... ldren: a single-center report.

@nl

prefLabel

Serum soluble urokinase-type p ...... ildren: a single-center report

@en

Serum soluble urokinase-type p ...... ldren: a single-center report.

@nl

P1433

Q37065608-28C201A2-9C41-433E-9010-59D49B689518

P1476

Q37065608-02E5264A-8868-4CF0-B4DA-217E4D5EFFFB

P2093

Q37065608-1CF01F30-1DD8-4A74-B375-ABCFF0574C35

Q37065608-40A03174-D73C-46DA-B121-269E66DCA334

Q37065608-717683CF-3915-4AEC-B4C6-BFE01009B91A

Q37065608-AC5EF61D-2536-491B-8DE5-A946FA6CCCCD

P2860

Q37065608-0340E723-1F25-4820-8EE6-85CBB2727790

Q37065608-05111637-55A8-4297-BC1B-5F74F74FC22E

Q37065608-1337C0A1-1499-4C93-8001-2EE297406D45

Q37065608-1627017E-63C5-41AB-A0AC-E734DF167186

Q37065608-2411EE49-F234-4FA9-91FD-24811FEA0FE4

Q37065608-354FEEF1-7A76-4695-82B2-A0664DC9EA5C

Q37065608-3B40C32C-FC5F-4747-8CC0-13EA8721BCC7

Q37065608-4B9AA90E-1008-40B5-A41D-9C2F7FE6AF71

Q37065608-4C7CE842-362A-4520-AFAA-E7BC20162032

Q37065608-5E9591A7-60D5-4062-AD90-27AE6AB70918

P304

Q37065608-84A33D3B-3E3A-4188-AA0C-B3DCD904A242

P31

Q37065608-1CB0F8DF-6FB6-469C-B38C-810DCC2F539F

P356

Q37065608-4A0AD83E-E0B5-4F29-A499-A8F6FCC94759

P433

Q37065608-C5B795B1-C91B-4CA0-B5DD-9F56F2B4F3B8

P478

Q37065608-57186CD9-9956-463E-8175-BB33D7E1E351

P577

Q37065608-1BA4EB74-2A86-4FA5-BB90-EB34955FF6FB

P698

Q37065608-A78A582E-62AA-4C8F-839F-B497D0BC494D

P932

Q37065608-42CCD066-004D-45EB-9359-9EE40673598F

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Serum soluble urokinase-type p ...... ildren: a single-center report

@en

P2093

Craig B Langman

http://www.w3.org/2001/XMLSchema#string

Heather E Price

http://www.w3.org/2001/XMLSchema#string

Lorenzo Gallon

http://www.w3.org/2001/XMLSchema#string

Margret E Bock

http://www.w3.org/2001/XMLSchema#string

P2860

Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review

New equations to estimate GFR in children with CKD

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.

Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and eli

Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.

Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis

Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients

Circulating suPAR in two cohorts of primary FSGS.

Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.

Focal segmental glomerulosclerosis.

P304

1304-1311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.07680712

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23620441

http://www.w3.org/2001/XMLSchema#string

P932

3731904

http://www.w3.org/2001/XMLSchema#string